0001559053-26-000017
SEC filingQ1 2026 delivered profitability with $51.1M revenue and $32.7M net income, reversing prior-year losses due to a Novo Nordisk milestone payment and significantly lower clinical trial and personnel expenses from program wind-downs.
Cash flow from operating activities flipped to $28.8 million provided, from $53.4 million used previously, driven by the working capital inflow from the Novo Nordisk milestone. This positive generation supports ongoing operations amid program transitions. The company repurchased ordinary shares, recording costs against additional paid-in capital, signaling management confidence in the trajectory post-restructuring.
Operationally, Prothena relies on third-party manufacturers for preclinical and clinical supplies, a strategy it plans to maintain. While the Brisbane Facility sublease provides necessary lab space, the company acknowledges the need for substantial additional capital to advance product candidates through development and regulatory approval, given inherent risks and uncertainties. Management notes potential future losses, emphasizing the biotech development path's volatility, but current liquidity from the milestone bolsters the balance sheet for near-term needs.